Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Studies have shown that Xeomin is not associated with the development of neutralizing antibodies in animal models or in patients. In conclusion, complexing proteins do not contribute to the stability of botulinum toxin type A drugs and do not contribute to their therapeutic effects, but may be associated with a secondary nonresponse due to the development of neutralizing antibodies.
Автор:  Jürgen Frevert, Dirk Dressler
Год публикации:  2010
Файл:  Загрузить